M3 Muscarinic Antagonist Tocolytic Therapy for Preterm Labor

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for preterm labor, such as tocolytic agents, are associated with significant side effects and are not entirely effective in preventing preterm delivery.

Innovation Solution

Administering a muscarinic antagonist, particularly those with high selectivity and affinity for the M3 receptor, to treat or prevent preterm labor, or to control the timing of parturition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tocolytic agents (β2-adrenergic agonists, magnesium sulfate, ethanol) are administered to treat preterm labor, then uterine contractions are reduced, but severe side effects occur (cardiovascular and metabolic effects in mother, respiratory depression, cardiac arrest risk)

Engineering Contradiction:

Improveeffectiveness in preventing preterm deliveryVSAvoidside effects on mother and fetus

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter from β2-adrenergic agonism or magnesium sulfate to muscarinic antagonism, specifically targeting M3 receptors in uterine smooth muscle. This parameter change achieves uterine relaxation through a different mechanism (blocking acetylcholine-mediated contraction) that avoids the cardiovascular and metabolic side effects of β2-agonists and the respiratory depression risks of magnesium sulfate

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces muscarinic antagonists as an intermediary substance that blocks the action of acetylcholine at muscarinic receptors in the uterus. This intermediary approach prevents the direct stimulation of uterine contractions by acetylcholine without triggering the harmful cascade of effects seen with other tocolytics, thereby reducing side effects while maintaining effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If ritodrine is administered to prevent premature labor, then preterm delivery is reduced, but cardiovascular and metabolic side effects occur (tachycardia, increased renin secretion, hyperglycemia)

Engineering Contradiction:

Improveprevention of preterm deliveryVSAvoidcardiovascular and metabolic side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts the beneficial tocolytic effect from the problematic β2-adrenergic agonist mechanism and implements it through a completely different pharmacological pathway (muscarinic antagonism). By taking out the uterine relaxation benefit while eliminating the β2-agonist side effect profile, the invention achieves prevention of preterm delivery without cardiovascular and metabolic harm

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs muscarinic antagonists as a temporary, targeted intervention that provides acute tocolytic protection without long-term metabolic disruption. The short-acting nature of these agents allows for controlled use to bridge preterm labor through the most critical period without causing sustained hyperglycemia or cardiovascular stress

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If magnesium sulfate is administered at high plasma concentrations to treat preterm labor, then uterine contractions are inhibited, but cardiac conduction inhibition and respiratory depression occur

Engineering Contradiction:

Improveinhibition of uterine contractionsVSAvoidcardiac conduction inhibition and respiratory depression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses muscarinic antagonists as an intermediary that blocks acetylcholine's effect on uterine smooth muscle without affecting cardiac conduction or respiratory centers. This intermediary mechanism achieves contraction inhibition selectively in the uterus while sparing the heart and respiratory system from magnesium sulfate's toxic effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent achieves local action in the uterus through muscarinic antagonism, concentrating the therapeutic effect where needed (uterine smooth muscle M3 receptors) while avoiding systemic effects on cardiac tissue and respiratory control centers. This localized approach prevents the dangerous systemic toxicity seen with high-dose magnesium sulfate

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20250073237A1Methods of treating or preventing preterm labor

Publication Date: 2025.03.06 VISCO ANTHONY G

AI summary

Described herein are methods for treating preterm labor, stopping labor prior to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering a chemical compound, such as a muscarinic receptor antagonist, preferably a M3 receptor antagonist, or a β-3 adrenergic agonist. Also described are methods for treating preterm labor, stopping labor preparatory to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering an effective amount of transdermal stimulation, posterior tibial nerve stimulation or another form of non-invasive or invasive neuromodulation, unstimulated or stimulated acupuncture, magnetic field therapy, or vibratory stimulation. These methods may be practiced individually, in combination with each other, or in combination with known tocolytic methods or medications.